SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022

22 Feb 2022 16:30:00 By Nasdaq GlobeNewswire

Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA

22 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

08 Dec 2021 08:30:00 By Nasdaq GlobeNewswire

Supernus Pharmaceuticals Targeted in Ransomware Incident

24 Nov 2021 18:58:37 By Nasdaq GlobeNewswire

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

24 Nov 2021 09:12:51 By Nasdaq GlobeNewswire

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

23 Nov 2021 08:00:00 By Nasdaq GlobeNewswire

Supernus to Participate in Annual Piper Sandler Healthcare Conference

18 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Supernus to Participate in Upcoming November Investor Conferences

10 Nov 2021 16:05:03 By Nasdaq GlobeNewswire

Supernus Announces Third Quarter 2021 Financial Results

03 Nov 2021 16:01:01 By Nasdaq GlobeNewswire

Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

27 Oct 2021 17:42:55 By Nasdaq GlobeNewswire

Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month

20 Oct 2021 08:00:02 By Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

11 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA

02 Sep 2021 18:45:00 By Nasdaq GlobeNewswire

Supernus to Participate in Upcoming September Investor Conferences

02 Sep 2021 09:00:00 By Nasdaq GlobeNewswire

Supernus Announces Second Quarter 2021 Financial Results

04 Aug 2021 16:09:33 By Nasdaq GlobeNewswire

Supernus to Host Second Quarter 2021 Financial Results Conference Call

22 Jul 2021 16:37:21 By Nasdaq GlobeNewswire

Supernus to Present at Jefferies Virtual Healthcare Conference

25 May 2021 08:30:00 By Nasdaq GlobeNewswire

Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age

24 May 2021 08:30:00 By Nasdaq GlobeNewswire

Supernus Announces First Quarter 2021 Financial Results

05 May 2021 16:01:00 By Nasdaq GlobeNewswire

Supernus Announces Paragraph IV ANDA Filing for XADAGO®

04 May 2021 20:49:10 By Nasdaq GlobeNewswire